argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 mrt 2016 - 17:45
Statutaire naam
argenx SE
Titel
argenx announces Annual General Meeting of Shareholders 28 April 2016
Bericht
Breda, the Netherlands - arGEN-X N.V. (Euronext Brussels: ARGX, hereinafter: the "Company"), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that an annual general meeting of shareholders will be held on Thursday 28 April 2016.
Datum laatste update: 01 september 2024